Cancer Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Cancer Pain Pipeline Drugs Market Overview

Cancer pain can be defined as a complex sensation that reflects both damages to the body and the body’s response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or skin, nerve, and other changes caused by either the body’s immune response or hormones released by the tumor. Cancer pain can be treated by analgesic drug therapy, non-opioid analgesics, opioid analgesics, adjuvant drugs, psychotherapy, anesthetic, and neurosurgical pain management.

The Cancer Pain pipeline drugs market research report provides comprehensive information on the therapeutics under development for Cancer Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects.

Cancer Pain Pipeline Drugs Market Segmentation by Targets

Some of the targets of the Cancer Pain pipeline drugs market are Mu Type Opioid Receptor, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Beta Nerve Growth Factor, Sodium Channel Protein Type 9 Subunit Alpha, Interleukin 1 Beta, Interleukin 18, and Sodium Channel Protein Type 10 Subunit Alpha.

Cancer Pain Pipeline Drugs Market Analysis, by Targets

For more Cancer Pain pipeline drugs market target insights, download a free report sample

Cancer Pain Pipeline Drugs Market Segmentation by Mechanism of Actions

Some of the mechanisms of action of the Cancer Pain pipeline drugs market are Mu Type Opioid Receptor Agonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Beta Nerve Growth Factor Inhibitor, Sodium Channel Protein Type 9 Subunit Alpha Blocker, Interleukin 1 Beta Inhibitor, Interleukin 18 Inhibitor, and Sodium Channel Protein Type 10 Subunit Alpha Blocker.

Cancer Pain Pipeline Drugs Market Analysis, by Mechanism of Actions

For more mechanism of action insights into the Cancer Pain pipeline drugs market, download a free report sample

Cancer Pain Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Cancer Pain pipeline drugs market are oral, intravenous, subcutaneous, nasal, transdermal, transmucosal, epidural, and inhalational.

Cancer Pain Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the Cancer Pain pipeline drugs market, download a free report sample

Cancer Pain Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the Cancer Pain pipeline drugs market are Small Molecule, Antisense Oligonucleotide, Monoclonal Antibody, Aptamer, Synthetic Peptide, and Peptide.

Cancer Pain Pipeline Drugs Market Analysis, by Molecule Types

For more molecule type insights into the Cancer Pain pipeline drugs market, download a free report sample

Competitive Landscape

Some of the key companies in the Cancer Pain pipeline drugs market are Klaria Pharma Holding AB, Komipharm International Co Ltd, Q-State Biosciences Inc, AfaSci Inc, Indaptus Therapeutics Inc, Akeso Inc, and Alexza Pharmaceuticals Inc.

Akeso Inc: Akeso Inc (Akeso) is a clinical-stage biopharmaceutical company that focuses on in-house discovery and development of mono and bi-specific antibody drugs. The company’s product pipeline includes Ak101 and Ak111 targeting plaque psoriasis; Ak102 for the treatment of hypercholesterolemia; Ak104 against cancer; Ak105 for treating anlotinib; and Ak112 against solid tumors.

The companu also provides kangfang integrated development platform (ACE Platform) which covers all drug R & D, including target verification, antibody discovery, and also development functions. The company works in partnership with MERCK & CO Inc, Dawnrays Pharmaceutical Holdings Ltd, Sino Biopharmaceutical Ltd, and China Biopharma. Akeso is headquartered in Zhongshan, Guangdong, China

Cancer Pain Pipeline Drugs Market Analysis, by Companies

To know more about the Cancer Pain pipeline drugs market companies, download a free report sample

Cancer Pain Pipeline Drugs Market Report Overview

Scope

This report provides:

• A snapshot of the global therapeutic landscape of Cancer Pain.
• Reviews of pipeline therapeutics for Cancer Pain by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
• Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• Reviews key companies involved in Cancer Pain therapeutics and enlists all their major and minor projects.
• Evaluation of Cancer Pain therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• All the dormant and discontinued pipeline projects.
• Reviews of the latest news related to pipeline therapeutics for Cancer Pain.

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Cancer Pain.
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding the Cancer Pain pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.